SpliceBio has dosed the first patient in the Part B dose-expansion portion of its phase 1/2 ASTRA clinical trial ( ...
After AT&T Fiber raised the price on my gigabit plan, I downgraded to 500 Mbps and found no drop in everyday performance — ...
Pancreatic cancer is notoriously hard to treat, often resisting therapies that target its most common mutations. Researchers ...
Pancreatic ductal adenocarcinoma (PDAC) is the most lethal form of pancreas cancer. It's also the most common form of the ...
They do a great job in splicing wires together and they come in a variety of sizes, says Ed Bukont of E2 Technical Service.
Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with ...
CSHL’s Krainer lab has discovered a key oncogenic circuit driving aggressive pancreatic ductal adenocarcinoma (PDAC) ...
SpliceBio, a clinical-stage genetic medicines company pioneering protein splicing to address diseases caused by mutations in large genes, today announced that the first patient has been dosed in the ...
The Krainer lab discovered a three-oncogene circuit that helps drive the aggressive progression of pancreatic ductal ...
Researchers at CSH Laboratory identified an oncogenic SRSF1–AURKA–MYC circuit driving pancreatic ductal adenocarcinoma.
New research provides a mechanistic map of how genetic mutations disrupt RNA splicing in acute myeloid leukemia.
Treating acute myeloid leukemia (AML) depends on knowing what goes wrong inside cells. A new study suggests that two genetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback